Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:OMER News 15 October 2025 - 25 December 2025

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

The FDA approved Omeros’ Yartemlea (narsoplimab-wuug) for adults and children with transplant-associated thrombotic microangiopathy, marking the first approved therapy for this condition. Omeros shares surged to a 52-week high after trading halts and heavy options activity. The company plans a U.S. launch in January 2026. Analysts renewed coverage following the regulatory decision.
25 December 2025
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros shares jumped 75% to $15.36 in after-hours trading Wednesday after the FDA approved its first commercial product, YARTEMLEA, for a rare post-transplant complication. The stock saw heavy volume and a wide range, with multiple trading halts reported. U.S. markets closed early for Christmas Eve and will reopen Friday. The FDA had previously rejected the drug in 2021.
24 December 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseasesinvestor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rightsinvestor.omeros.comreuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the newsreuters.com, and by market close had settled near $10.10investing.com. TechStock² (ts2.tech) notes Omeros shares surged roughly 65% on the announcementts2.tech. The deal is structured as an asset purchase and license – not
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties Novonordisk. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug Reuters. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 Marketscreener Novonordisk. Novo’s Chief Scientific
15 October 2025
···

Stock Market Today

SMIC stock set for results test this week as Hong Kong market reopens

SMIC stock set for results test this week as Hong Kong market reopens

8 February 2026
SMIC shares closed up 0.22% at HK$67.60 on Friday in Hong Kong. The board will announce unaudited results on Feb. 10, and shareholders vote Feb. 12 on acquiring the remaining 49% of SMNC. The register of members closes Feb. 9–12. SMIC plans to pay mainly with new RMB shares.
MediaTek stock price drops 3.4% as Taiwan market shuts; what investors watch next week

MediaTek stock price drops 3.4% as Taiwan market shuts; what investors watch next week

8 February 2026
MediaTek shares closed down 3.4% at NT$1,710 on Friday in Taipei, with 11.8 million shares traded before the market shut for the weekend. The company said it will double investment in data-center chips and advanced packaging, while warning of rising supply chain costs. Fourth-quarter sales rose 8.8% to NT$150.2 billion, but net income slipped 3.6%. Investors face uncertainty ahead of the Lunar New Year break and a weaker tech sector mood.
Go toTop